Cargando…

Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability

There are many kinds of biological activities of resveratrol itself, but its clinical application is limited by its poor solubility in water and low bioavailability. Therefore, we have prepared glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles (GL-HSA-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Mingfang, Zhong, Chen, Deng, Yiping, Zhang, Qian, Zhang, Xiaoxue, Zhao, Xiuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968672/
https://www.ncbi.nlm.nih.gov/pubmed/31858857
http://dx.doi.org/10.1080/10717544.2019.1704944
_version_ 1783489183407407104
author Wu, Mingfang
Zhong, Chen
Deng, Yiping
Zhang, Qian
Zhang, Xiaoxue
Zhao, Xiuhua
author_facet Wu, Mingfang
Zhong, Chen
Deng, Yiping
Zhang, Qian
Zhang, Xiaoxue
Zhao, Xiuhua
author_sort Wu, Mingfang
collection PubMed
description There are many kinds of biological activities of resveratrol itself, but its clinical application is limited by its poor solubility in water and low bioavailability. Therefore, we have prepared glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles (GL-HSA-RESNPs). The purpose of this study was to investigate the bioavailability, pharmacokinetics and tissue distribution of resveratrol in rats after single-dose tail vein injection administration of GL-HSA-RESNPs. A sensitive and reliable high performance liquid chromatography (HPLC) method was established to verify the content of resveratrol in rat plasma and organs. The C(max) value after GL-HSA-RESNPs administration was significantly higher than that of resveratrol suspension (933 ± 76.64 ng/mL vs. 618 ± 42.54 ng/mL, p < .01). The T(max) value obtained after GL-HSA-RESNPs administration was significantly shorter than that after resveratrol suspension administration (0.17 ± 0.01 h vs. 0.25 ± 0.01 h, p < .001). The bioavailability of GL-HSA-RESNPs was 4.25 times higher than that of the pure resveratrol. The concentration of resveratrol in the main organs of rats treated with the GL-HSA-RESNPs was higher than that in rats treated with the pure resveratrol. Rats treated with GL-HSA-RESNPs had the highest concentration of resveratrol in their liver. It is indicated that GL-HSA-RESNPs is a promising liver-targeted delivery system that improves the in vivo bioavailability of resveratrol.
format Online
Article
Text
id pubmed-6968672
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-69686722020-01-31 Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability Wu, Mingfang Zhong, Chen Deng, Yiping Zhang, Qian Zhang, Xiaoxue Zhao, Xiuhua Drug Deliv Research Article There are many kinds of biological activities of resveratrol itself, but its clinical application is limited by its poor solubility in water and low bioavailability. Therefore, we have prepared glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles (GL-HSA-RESNPs). The purpose of this study was to investigate the bioavailability, pharmacokinetics and tissue distribution of resveratrol in rats after single-dose tail vein injection administration of GL-HSA-RESNPs. A sensitive and reliable high performance liquid chromatography (HPLC) method was established to verify the content of resveratrol in rat plasma and organs. The C(max) value after GL-HSA-RESNPs administration was significantly higher than that of resveratrol suspension (933 ± 76.64 ng/mL vs. 618 ± 42.54 ng/mL, p < .01). The T(max) value obtained after GL-HSA-RESNPs administration was significantly shorter than that after resveratrol suspension administration (0.17 ± 0.01 h vs. 0.25 ± 0.01 h, p < .001). The bioavailability of GL-HSA-RESNPs was 4.25 times higher than that of the pure resveratrol. The concentration of resveratrol in the main organs of rats treated with the GL-HSA-RESNPs was higher than that in rats treated with the pure resveratrol. Rats treated with GL-HSA-RESNPs had the highest concentration of resveratrol in their liver. It is indicated that GL-HSA-RESNPs is a promising liver-targeted delivery system that improves the in vivo bioavailability of resveratrol. Taylor & Francis 2019-12-20 /pmc/articles/PMC6968672/ /pubmed/31858857 http://dx.doi.org/10.1080/10717544.2019.1704944 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wu, Mingfang
Zhong, Chen
Deng, Yiping
Zhang, Qian
Zhang, Xiaoxue
Zhao, Xiuhua
Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability
title Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability
title_full Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability
title_fullStr Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability
title_full_unstemmed Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability
title_short Resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection II: pharmacokinetics, tissue distribution and bioavailability
title_sort resveratrol loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles for tail vein injection ii: pharmacokinetics, tissue distribution and bioavailability
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968672/
https://www.ncbi.nlm.nih.gov/pubmed/31858857
http://dx.doi.org/10.1080/10717544.2019.1704944
work_keys_str_mv AT wumingfang resveratrolloadedglycyrrhizicacidconjugatedhumanserumalbuminnanoparticlesfortailveininjectioniipharmacokineticstissuedistributionandbioavailability
AT zhongchen resveratrolloadedglycyrrhizicacidconjugatedhumanserumalbuminnanoparticlesfortailveininjectioniipharmacokineticstissuedistributionandbioavailability
AT dengyiping resveratrolloadedglycyrrhizicacidconjugatedhumanserumalbuminnanoparticlesfortailveininjectioniipharmacokineticstissuedistributionandbioavailability
AT zhangqian resveratrolloadedglycyrrhizicacidconjugatedhumanserumalbuminnanoparticlesfortailveininjectioniipharmacokineticstissuedistributionandbioavailability
AT zhangxiaoxue resveratrolloadedglycyrrhizicacidconjugatedhumanserumalbuminnanoparticlesfortailveininjectioniipharmacokineticstissuedistributionandbioavailability
AT zhaoxiuhua resveratrolloadedglycyrrhizicacidconjugatedhumanserumalbuminnanoparticlesfortailveininjectioniipharmacokineticstissuedistributionandbioavailability